{
  "directed": true,
  "multigraph": true,
  "graph": {
    "pybel_version": "0.13.0",
    "document_metadata": {
      "copyright": "Copyright Â© 2018 Fraunhofer Institute SCAI, All rights reserved.",
      "licenses": "CC BY 4.0",
      "contact": "charles.hoyt@scai.fraunhofer.de",
      "name": "Tau Antibody Targeting Pathological Species Blocks Neuronal Uptake and Interneuron Propagation of Tau in Vitro",
      "version": "1.0.0",
      "authors": "Rana Aldisi",
      "description": "This file encodes the article Tau Antibody Targeting Pathological Species Blocks Neuronal Uptake and Interneuron Propagation of Tau in Vitro by Nobuhara et. al. 2017"
    },
    "namespace_url": {
      "CHEBI": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/chebi-names.belns",
      "DRUGBANK": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/drugbank-names.belns",
      "ECCODE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/ec-code.belns",
      "HBP": "https://raw.githubusercontent.com/pharmacome/terminology/7e4be528f12abd28be768b62402fba6e083eaf9e/export/hbp-names.belns",
      "HGNC": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/hgnc-names.belns",
      "HGNCGENEFAMILY": "https://raw.githubusercontent.com/pharmacome/terminology/3074b85b858455d8eeb76cfcdef685ced19bbe11/external/hgnc.genefamily-names.belns",
      "GO": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/go-names.belns",
      "INTERPRO": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/interpro-names.belns",
      "MESH": "https://raw.githubusercontent.com/pharmacome/terminology/01c9daa61012b37dd0a1bc962521ba51a15b38f1/external/mesh-names.belns",
      "MGI": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/mgi-names.belns",
      "MIRBASE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/mirbase-names.belns",
      "NCBIGENE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/entrez.belns",
      "PFAM": "https://raw.githubusercontent.com/pharmacome/terminology/8ccfed235e418e4c8aa576f9a5ef0f838e794c7f/external/pfam-names.belns",
      "RGD": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/rgd-names.belns",
      "FPLX": "https://raw.githubusercontent.com/sorgerlab/famplex/e8ae9926ff95266032cb74f77973c84939bffbeb/export/famplex.belns",
      "CTO": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/clinical-trial-ontology/clinical-trial-ontology-1.0.0.belns",
      "DO": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/disease-ontology/disease-ontology-20170725.belns",
      "HP": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hp/hp-20171108.belns",
      "SCOMP": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-named-complexes/selventa-named-complexes-20170725.belns",
      "SFAM": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-protein-families/selventa-protein-families-20170725.belns"
    },
    "namespace_pattern": {
      "DBSNP": "rs[0-9]+",
      "TAXONOMY": "^\\d+$",
      "UNIPROT": "^([A-N,R-Z][0-9]([A-Z][A-Z, 0-9][A-Z, 0-9][0-9]){1,2})|([O,P,Q][0-9][A-Z, 0-9][A-Z, 0-9][A-Z, 0-9][0-9])(\\.\\d+)?$",
      "PUBCHEM": "^\\d+$"
    },
    "namespaces_uncached": [],
    "annotation_url": {
      "Anatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno",
      "CellLine": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno",
      "CellStructure": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno",
      "Cell": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno",
      "Confidence": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno",
      "Disease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno",
      "Gender": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno",
      "MeSHAnatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno",
      "MeSHDisease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno",
      "Subgraph": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno",
      "TextLocation": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"
    },
    "annotation_pattern": {
      "Species": "^\\d+$"
    },
    "annotation_list": {
      "HasQuantitativeInformation": [
        "False",
        "True"
      ]
    },
    "path": "/Users/cthoyt/dev/knowledge/hbp_knowledge/nobuhara2017.bel"
  },
  "nodes": [
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "Tau aggregates",
      "id": "2f93b798e33773ea9681389870bbee41f6fa7ee04c087bda4bd1492520385f58d089a7261b1353e15c31d3e29a96ff31884886e6ab9fa477ef8f63f19cf154f7"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "Tau antibody, 40E8",
      "id": "b9dc79a894f3563277e1780335b6b791671aed2b5c99c4cff346dd7dc034cf7a2f45aff6aa7a6c5a68b004a8a90a7cc651a36c5faedbac5019bc83f21261302d"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "Tau antibody, 4E4",
      "id": "8eed4b182f960a400672aca57c1caac418b10fb6cdad65476a8123a5ac2427e9ab65276dcf841191d050f6f512a636a1c6b791495c1666173485f29c7a8990df"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "Tau antibody, 6C5",
      "id": "75d69ed8f2e82470c05e8a5b8333acdb941701ab8318232c93304bf9ead4aeab9246a8a054a450b686c80255053cd4a3ef8efef3fc21544be3f2411e6c66cfef"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "Tau antibody, HT7",
      "id": "2c933117e44943666fb287dd3340f308fbb6f1c8b457f1a0dbc087ca3fd86ff5f17d817822b6a9cd9e701507bda214fc702328a7483b0988767acb5750737826"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "Tau antibody, Tau-13",
      "id": "b7b8d7d03df7eb96369cda8cfe835c1d265bc283f7b3fe07c9edec9c467416b3b8397888a00dad20b17707b8fc986e7c370c2fb6191419c14a8602bdf4124c07"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "Tau antibody, Tau46",
      "id": "e19e5ea13e038f7bd9a4ba984096f537b6c0ab0e7b957715649f90de7fb847965d680b516b91af27ba760840cd342135bbcfb306788010e11553a35aba3c9a4c"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "Tau antibody, pS396",
      "id": "bce171e6abc27abe31bbf906c70cafa1a52e04542d8f15aca67aa1a53cd2ad9a3fbde4bee5c0d4128c35953c56c45a11f9e57de3c2359edf498b1acfae246eab"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "id": "ad82d360f02888e890bb2d1f91d1dc020c21cebed2b4eed0193a58e6b396b5f0797d607568dea382c05ffe2a003537d10190b020739af8d51c8d7dbc19bf5ab1"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "MAPT",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          }
        }
      ],
      "id": "526bae251987f8c4f55f6e2451662fa55e087c57585beae7c389b020d73487c739834e9b8ec841783de6a5b5fb9df8b138e9eff4406a9ec5e606766575dcac0e"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Mapt",
      "id": "7d94454106658b1e4190b417a419f7ccbab4b525157cd679cbb4da8a006b08c3819b0a360b692358b3f80ea2648890248be2aa7c97e1d59962dc6aa097560f2d"
    }
  ],
  "links": [
    {
      "line": 98,
      "relation": "decreases",
      "evidence": "Among the seven antibodies, Tau13 and 6C5 most efficiently removed tau (>85% reduction) from rTg4510 brain extracts on immunodepletion (Figure 2A). HT7 showed an intermediate effect (72% reduction), whereas the other four antibodies (40E8, 4E4, p396, and Tau46) removed only a small fraction of tau (5.6%, 16.6%, 8.4%, and 18% reductions, respectively) (Figure 2A).",
      "citation": {
        "type": "PubMed",
        "reference": "28408124"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "Species": {
          "10090": true
        },
        "MeSHDisease": {
          "Tauopathies": true
        },
        "HasQuantitativeInformation": {
          "True": true
        }
      },
      "object": {
        "location": {
          "namespace": "GO",
          "name": "cell"
        }
      },
      "source": 5,
      "target": 10,
      "key": "4a307148cabcd0d46afa284ae27da9309b458102ea808130055768f01c1a27c2c773212289a17bc27e60c08ae0b54c0ab66483531de17d4c70472375558c2465"
    },
    {
      "line": 123,
      "relation": "decreases",
      "evidence": "Confocal FRET image analysis showed robust tau aggregation in primary neurons treated with control IgG-immunodepleted rTg4510 brain extracts (Figure 2, B and C).The 6C5 antibody most successfully reduced tau uptake by immunodepletion (>90% reduction), and Tau13 and HT7 showed intermediate effects (approximately 60% reductions) (Figure 2, B and C)",
      "citation": {
        "type": "PubMed",
        "reference": "28408124"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "Species": {
          "10090": true
        },
        "MeSHDisease": {
          "Tauopathies": true
        },
        "HasQuantitativeInformation": {
          "True": true
        }
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GO",
            "name": "extracellular region"
          },
          "toLoc": {
            "namespace": "GO",
            "name": "intracellular"
          }
        }
      },
      "source": 5,
      "target": 10,
      "key": "d02881aa1f6ecc8052d1a94bdac520533b1b86591b28421f178fe578f5d2650fa51d22c5f42ae0ea904611b8e72b360f94622062faf6a8eb81a4a63131fd1291"
    },
    {
      "line": 155,
      "relation": "decreases",
      "evidence": "Tau13, 6C5, and HT7 efficiently depleted tau from the AD HMW fraction (97%, 82%, and 72%, respectively), whereas the other four antibodies (40E8, 4E4, p396, and Tau46) removed only a small fraction of tau (33%, 4.7%, 22%, and 21% reductions, respectively) (Figure 4A).",
      "citation": {
        "type": "PubMed",
        "reference": "28408124"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "HasQuantitativeInformation": {
          "True": true
        }
      },
      "object": {
        "location": {
          "namespace": "GO",
          "name": "cell"
        }
      },
      "source": 5,
      "target": 8,
      "key": "2a9f7982364bc873b5bcff7bf8711c659f379ad5a98f208e459886fc97619d6ba312e4c9001200f515e7ac61f11cd744de0606bafd3510d783fd312fc821aabb"
    },
    {
      "line": 177,
      "relation": "decreases",
      "evidence": "In the tau uptake assay, 6C5 most effectively reduced tau uptake by immunodepletion (75% reduction) (Figure 4, B and C). Tau13 and HT7 showed intermediate effects (55% and 47% reductions, respectively) (Figure 4, B and C). The 40E8, p396, and 4E4 antibodies also reduced neuronal tau uptake (65%, 53%, and 47% reductions, respectively), despite their low immunodepletion efficiency (Figure 4).",
      "citation": {
        "type": "PubMed",
        "reference": "28408124"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "MeSHAnatomy": {
          "Neurons": true
        },
        "HasQuantitativeInformation": {
          "True": true
        }
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GO",
            "name": "extracellular region"
          },
          "toLoc": {
            "namespace": "GO",
            "name": "intracellular"
          }
        }
      },
      "source": 5,
      "target": 8,
      "key": "48c0ba0eba398dcf72407657252e8fc65e6ef1c26300b0778fbcb81ed829050e93ee267d8ca80996eec2ecd1fd2f79e9204750fd797279027b0742146fdef111"
    },
    {
      "line": 118,
      "relation": "increases",
      "evidence": "Confocal FRET image analysis showed robust tau aggregation in primary neurons treated with control IgG-immunodepleted rTg4510 brain extracts (Figure 2, B and C).The 6C5 antibody most successfully reduced tau uptake by immunodepletion (>90% reduction), and Tau13 and HT7 showed intermediate effects (approximately 60% reductions) (Figure 2, B and C)",
      "citation": {
        "type": "PubMed",
        "reference": "28408124"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "Species": {
          "10090": true
        },
        "MeSHDisease": {
          "Tauopathies": true
        }
      },
      "subject": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GO",
            "name": "extracellular region"
          },
          "toLoc": {
            "namespace": "GO",
            "name": "intracellular"
          }
        }
      },
      "source": 10,
      "target": 0,
      "key": "e19afce1c3b204fadf5030636ee50e8766f2c984eecdf63519db8c9c1b3bb7cb589f8118bcbe37bf92b020321bbbf46cbcb0556cd6cbf80501633e1245cfd5bc"
    },
    {
      "line": 99,
      "relation": "decreases",
      "evidence": "Among the seven antibodies, Tau13 and 6C5 most efficiently removed tau (>85% reduction) from rTg4510 brain extracts on immunodepletion (Figure 2A). HT7 showed an intermediate effect (72% reduction), whereas the other four antibodies (40E8, 4E4, p396, and Tau46) removed only a small fraction of tau (5.6%, 16.6%, 8.4%, and 18% reductions, respectively) (Figure 2A).",
      "citation": {
        "type": "PubMed",
        "reference": "28408124"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "Species": {
          "10090": true
        },
        "MeSHDisease": {
          "Tauopathies": true
        },
        "HasQuantitativeInformation": {
          "True": true
        }
      },
      "object": {
        "location": {
          "namespace": "GO",
          "name": "cell"
        }
      },
      "source": 3,
      "target": 10,
      "key": "348369b4fec85f07b78481a65e46a1f98e93ad615b22524294f3cce60f1bb6b6bdbc4f229a282099ac8dbad169c9a9ff1056cbce1a9d6e66fefd1eb998cb3c34"
    },
    {
      "line": 121,
      "relation": "decreases",
      "evidence": "Confocal FRET image analysis showed robust tau aggregation in primary neurons treated with control IgG-immunodepleted rTg4510 brain extracts (Figure 2, B and C).The 6C5 antibody most successfully reduced tau uptake by immunodepletion (>90% reduction), and Tau13 and HT7 showed intermediate effects (approximately 60% reductions) (Figure 2, B and C)",
      "citation": {
        "type": "PubMed",
        "reference": "28408124"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "Species": {
          "10090": true
        },
        "MeSHDisease": {
          "Tauopathies": true
        },
        "HasQuantitativeInformation": {
          "True": true
        }
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GO",
            "name": "extracellular region"
          },
          "toLoc": {
            "namespace": "GO",
            "name": "intracellular"
          }
        }
      },
      "source": 3,
      "target": 10,
      "key": "1c6f34816451651b11cfe416417f45beef919c814769df075876d3ad594c6eb727c8a39a98cfa5d87539ecbf4cc513646c6a0d93a3ad53dc6b6bc40c19f989d1"
    },
    {
      "line": 156,
      "relation": "decreases",
      "evidence": "Tau13, 6C5, and HT7 efficiently depleted tau from the AD HMW fraction (97%, 82%, and 72%, respectively), whereas the other four antibodies (40E8, 4E4, p396, and Tau46) removed only a small fraction of tau (33%, 4.7%, 22%, and 21% reductions, respectively) (Figure 4A).",
      "citation": {
        "type": "PubMed",
        "reference": "28408124"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "HasQuantitativeInformation": {
          "True": true
        }
      },
      "object": {
        "location": {
          "namespace": "GO",
          "name": "cell"
        }
      },
      "source": 3,
      "target": 8,
      "key": "7f25b4fe74443a8c9b806ccdf1c028ad1f499972aa0d849f0abcab17113697d311a578d89126e1f101f261de3b51b5bc3af1b68ebbf4ea2bc59c5b46e02bbc5f"
    },
    {
      "line": 175,
      "relation": "decreases",
      "evidence": "In the tau uptake assay, 6C5 most effectively reduced tau uptake by immunodepletion (75% reduction) (Figure 4, B and C). Tau13 and HT7 showed intermediate effects (55% and 47% reductions, respectively) (Figure 4, B and C). The 40E8, p396, and 4E4 antibodies also reduced neuronal tau uptake (65%, 53%, and 47% reductions, respectively), despite their low immunodepletion efficiency (Figure 4).",
      "citation": {
        "type": "PubMed",
        "reference": "28408124"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "MeSHAnatomy": {
          "Neurons": true
        },
        "HasQuantitativeInformation": {
          "True": true
        }
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GO",
            "name": "extracellular region"
          },
          "toLoc": {
            "namespace": "GO",
            "name": "intracellular"
          }
        }
      },
      "source": 3,
      "target": 8,
      "key": "927a310379994eeb17a7d9ea6342d54e85d88c84e4a027a06f61529186620e731cdf6b3d4b8ba51a473d8522ff302e28360cf4b362bdce2f2bf6b0dc0084a16d"
    },
    {
      "line": 208,
      "relation": "decreases",
      "evidence": "for example, the two phosphorylation dependent tau antibodies (40E8 and p396) were the most efficient in the human AD case with the highest level of phosphorylated tau (1266). Both 6C5 and 40E8, shown to be most effective at reducing uptake from HMW human AD brainederived tau species (Figure 3, B and C), immunostained NFTs and neuritic plaques in postmortem human AD frontal cortex sections (Figure 6); 40E8 was somewhat more reactive to neuropil threads under the conditions used.",
      "citation": {
        "type": "PubMed",
        "reference": "28408124"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 3,
      "target": 8,
      "key": "815d045ffbb58afb853ed22f051b34637a7281c7f0a16819764b83a60c1fc22c4372bbfb2060ed4252b7a267d7c418f15c8f93b54ef3802ba67343af513441f8"
    },
    {
      "line": 215,
      "relation": "decreases",
      "evidence": "This result is consistent with the idea that the 6C5 antibody can slow tau uptake even after neurons have been exposed to the pathological tau and the uptake process initiated.",
      "citation": {
        "type": "PubMed",
        "reference": "28408124"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GO",
            "name": "extracellular region"
          },
          "toLoc": {
            "namespace": "GO",
            "name": "intracellular"
          }
        }
      },
      "source": 3,
      "target": 8,
      "key": "6a43f913928c2299f0dd679ea02eb49ca9a69134d7bcb874f3b65a55824caa0fa84ba4ec4b2dde9fd68809bd159a4fc4778d8b9481e097b3d79e3e42cbd4f42a"
    },
    {
      "line": 100,
      "relation": "decreases",
      "evidence": "Among the seven antibodies, Tau13 and 6C5 most efficiently removed tau (>85% reduction) from rTg4510 brain extracts on immunodepletion (Figure 2A). HT7 showed an intermediate effect (72% reduction), whereas the other four antibodies (40E8, 4E4, p396, and Tau46) removed only a small fraction of tau (5.6%, 16.6%, 8.4%, and 18% reductions, respectively) (Figure 2A).",
      "citation": {
        "type": "PubMed",
        "reference": "28408124"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "Species": {
          "10090": true
        },
        "MeSHDisease": {
          "Tauopathies": true
        },
        "HasQuantitativeInformation": {
          "True": true
        }
      },
      "object": {
        "location": {
          "namespace": "GO",
          "name": "cell"
        }
      },
      "source": 4,
      "target": 10,
      "key": "0be9a8ff36bf625a194544953fff84e2c9fdaaeedbd54aad1e7a41ab1976259a0778cd9d1dfa08c3b086151595a28b9a1242434d56989c15c366517d08a77674"
    },
    {
      "line": 122,
      "relation": "decreases",
      "evidence": "Confocal FRET image analysis showed robust tau aggregation in primary neurons treated with control IgG-immunodepleted rTg4510 brain extracts (Figure 2, B and C).The 6C5 antibody most successfully reduced tau uptake by immunodepletion (>90% reduction), and Tau13 and HT7 showed intermediate effects (approximately 60% reductions) (Figure 2, B and C)",
      "citation": {
        "type": "PubMed",
        "reference": "28408124"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "Species": {
          "10090": true
        },
        "MeSHDisease": {
          "Tauopathies": true
        },
        "HasQuantitativeInformation": {
          "True": true
        }
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GO",
            "name": "extracellular region"
          },
          "toLoc": {
            "namespace": "GO",
            "name": "intracellular"
          }
        }
      },
      "source": 4,
      "target": 10,
      "key": "45bfa2d1732414bb74a4598b315cf37b170e161889139b7e69e503c07dc3699a334ca1f56a853adb116ed2d31ff1017615a4623bd6c10a948aa737ed5886a582"
    },
    {
      "line": 157,
      "relation": "decreases",
      "evidence": "Tau13, 6C5, and HT7 efficiently depleted tau from the AD HMW fraction (97%, 82%, and 72%, respectively), whereas the other four antibodies (40E8, 4E4, p396, and Tau46) removed only a small fraction of tau (33%, 4.7%, 22%, and 21% reductions, respectively) (Figure 4A).",
      "citation": {
        "type": "PubMed",
        "reference": "28408124"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "HasQuantitativeInformation": {
          "True": true
        }
      },
      "object": {
        "location": {
          "namespace": "GO",
          "name": "cell"
        }
      },
      "source": 4,
      "target": 8,
      "key": "ceddc19c8eff2814295917db56b016f269bd86f93c74930f7c270f000cbf3b187b86ee5753aa8b45d8be845cf7948dddbd729e19e42045e0914d2ce1cd597348"
    },
    {
      "line": 176,
      "relation": "decreases",
      "evidence": "In the tau uptake assay, 6C5 most effectively reduced tau uptake by immunodepletion (75% reduction) (Figure 4, B and C). Tau13 and HT7 showed intermediate effects (55% and 47% reductions, respectively) (Figure 4, B and C). The 40E8, p396, and 4E4 antibodies also reduced neuronal tau uptake (65%, 53%, and 47% reductions, respectively), despite their low immunodepletion efficiency (Figure 4).",
      "citation": {
        "type": "PubMed",
        "reference": "28408124"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "MeSHAnatomy": {
          "Neurons": true
        },
        "HasQuantitativeInformation": {
          "True": true
        }
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GO",
            "name": "extracellular region"
          },
          "toLoc": {
            "namespace": "GO",
            "name": "intracellular"
          }
        }
      },
      "source": 4,
      "target": 8,
      "key": "69e3583e4020a941c4f9a11353ebafa9253400cf8d2323a83d68ea35aff21d8b17ca89febdbb22d373841285bd04b5844252da5d0cac1935ee44541e9c853f28"
    },
    {
      "line": 101,
      "relation": "decreases",
      "evidence": "Among the seven antibodies, Tau13 and 6C5 most efficiently removed tau (>85% reduction) from rTg4510 brain extracts on immunodepletion (Figure 2A). HT7 showed an intermediate effect (72% reduction), whereas the other four antibodies (40E8, 4E4, p396, and Tau46) removed only a small fraction of tau (5.6%, 16.6%, 8.4%, and 18% reductions, respectively) (Figure 2A).",
      "citation": {
        "type": "PubMed",
        "reference": "28408124"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "Species": {
          "10090": true
        },
        "MeSHDisease": {
          "Tauopathies": true
        },
        "HasQuantitativeInformation": {
          "True": true
        }
      },
      "object": {
        "location": {
          "namespace": "GO",
          "name": "cell"
        }
      },
      "source": 1,
      "target": 10,
      "key": "95d6d9b1cf98872725e6e7b6949909d31e040fd83f730bcdebd84b5cba6d84632ea6380248972aec10a9c22c337d5a38eb502654f8853e6c81d62984d2f2ac20"
    },
    {
      "line": 136,
      "relation": "decreases",
      "evidence": "The 40E8, 4E4, and p396 antibodies also reduced neuronal tau uptake by 40% to 80%, despite their low-immunodepletion efficiency (Figure 2). This finding suggests that they interacted with tau species that are prone to cellular uptake, which account for only a small fraction of all soluble tau species in the brain extract. Notably, Tau46 had little effect on tau uptake (Figure 2, B and C).",
      "citation": {
        "type": "PubMed",
        "reference": "28408124"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "Species": {
          "10090": true
        },
        "MeSHDisease": {
          "Tauopathies": true
        },
        "HasQuantitativeInformation": {
          "True": true
        }
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GO",
            "name": "extracellular region"
          },
          "toLoc": {
            "namespace": "GO",
            "name": "intracellular"
          }
        }
      },
      "source": 1,
      "target": 10,
      "key": "9ad67f7c83084446d18cc31fa3d55c808e6e07945b9d61ac5538c7df97eaf391debddd2e48376719f2e4f8eaa1c849a22e4aef74bd97dc008eb2e50aa843a11b"
    },
    {
      "line": 158,
      "relation": "decreases",
      "evidence": "Tau13, 6C5, and HT7 efficiently depleted tau from the AD HMW fraction (97%, 82%, and 72%, respectively), whereas the other four antibodies (40E8, 4E4, p396, and Tau46) removed only a small fraction of tau (33%, 4.7%, 22%, and 21% reductions, respectively) (Figure 4A).",
      "citation": {
        "type": "PubMed",
        "reference": "28408124"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "HasQuantitativeInformation": {
          "True": true
        }
      },
      "object": {
        "location": {
          "namespace": "GO",
          "name": "cell"
        }
      },
      "source": 1,
      "target": 8,
      "key": "7c6ee949678138f47d1d43c04d772fde9ae71d2d7a53e4f2f59b51f86f836a8f403e6f75d1edac9ef6202e3333fe8c6b4a8890f2d24508707afdd2110960a348"
    },
    {
      "line": 178,
      "relation": "decreases",
      "evidence": "In the tau uptake assay, 6C5 most effectively reduced tau uptake by immunodepletion (75% reduction) (Figure 4, B and C). Tau13 and HT7 showed intermediate effects (55% and 47% reductions, respectively) (Figure 4, B and C). The 40E8, p396, and 4E4 antibodies also reduced neuronal tau uptake (65%, 53%, and 47% reductions, respectively), despite their low immunodepletion efficiency (Figure 4).",
      "citation": {
        "type": "PubMed",
        "reference": "28408124"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "MeSHAnatomy": {
          "Neurons": true
        },
        "HasQuantitativeInformation": {
          "True": true
        }
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GO",
            "name": "extracellular region"
          },
          "toLoc": {
            "namespace": "GO",
            "name": "intracellular"
          }
        }
      },
      "source": 1,
      "target": 8,
      "key": "9e572109bc5162bcd1972e4dc1198657211c7791ee00de90e9a4124006b4c59f99155eeec5945d2aa13598e4ae51a3dffa7300d2f802fefe48ad7ec83fba3d37"
    },
    {
      "line": 207,
      "relation": "decreases",
      "evidence": "for example, the two phosphorylation dependent tau antibodies (40E8 and p396) were the most efficient in the human AD case with the highest level of phosphorylated tau (1266). Both 6C5 and 40E8, shown to be most effective at reducing uptake from HMW human AD brainederived tau species (Figure 3, B and C), immunostained NFTs and neuritic plaques in postmortem human AD frontal cortex sections (Figure 6); 40E8 was somewhat more reactive to neuropil threads under the conditions used.",
      "citation": {
        "type": "PubMed",
        "reference": "28408124"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 1,
      "target": 8,
      "key": "432045858e9568fa4822a9e962a1b05c10fec9fb3e51820bb72390136de160fa6872f908ad161af94e6a177ee62c444dee928b495d6a48d1ce15b4f8988a6812"
    },
    {
      "line": 205,
      "relation": "decreases",
      "evidence": "for example, the two phosphorylation dependent tau antibodies (40E8 and p396) were the most efficient in the human AD case with the highest level of phosphorylated tau (1266). Both 6C5 and 40E8, shown to be most effective at reducing uptake from HMW human AD brainederived tau species (Figure 3, B and C), immunostained NFTs and neuritic plaques in postmortem human AD frontal cortex sections (Figure 6); 40E8 was somewhat more reactive to neuropil threads under the conditions used.",
      "citation": {
        "type": "PubMed",
        "reference": "28408124"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 1,
      "target": 9,
      "key": "d59e3b0e59d5b6267c7184505a384c6b17a1cadcb5bcd45f5cab5545a0fed42c1e3ec8ada74f6bac5e82d312eb0f85ce9ab1a35d84b7d3ad8f5da64b9d8d6e8c"
    },
    {
      "line": 102,
      "relation": "decreases",
      "evidence": "Among the seven antibodies, Tau13 and 6C5 most efficiently removed tau (>85% reduction) from rTg4510 brain extracts on immunodepletion (Figure 2A). HT7 showed an intermediate effect (72% reduction), whereas the other four antibodies (40E8, 4E4, p396, and Tau46) removed only a small fraction of tau (5.6%, 16.6%, 8.4%, and 18% reductions, respectively) (Figure 2A).",
      "citation": {
        "type": "PubMed",
        "reference": "28408124"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "Species": {
          "10090": true
        },
        "MeSHDisease": {
          "Tauopathies": true
        },
        "HasQuantitativeInformation": {
          "True": true
        }
      },
      "object": {
        "location": {
          "namespace": "GO",
          "name": "cell"
        }
      },
      "source": 7,
      "target": 10,
      "key": "44a3c7889bfeb9dacd064c033606247a199afaf26c70fef023283f3661912d406f5521f23b210ece27e76327d4a67c878ee23237e942902130c7be2d892d6c1d"
    },
    {
      "line": 137,
      "relation": "decreases",
      "evidence": "The 40E8, 4E4, and p396 antibodies also reduced neuronal tau uptake by 40% to 80%, despite their low-immunodepletion efficiency (Figure 2). This finding suggests that they interacted with tau species that are prone to cellular uptake, which account for only a small fraction of all soluble tau species in the brain extract. Notably, Tau46 had little effect on tau uptake (Figure 2, B and C).",
      "citation": {
        "type": "PubMed",
        "reference": "28408124"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "Species": {
          "10090": true
        },
        "MeSHDisease": {
          "Tauopathies": true
        },
        "HasQuantitativeInformation": {
          "True": true
        }
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GO",
            "name": "extracellular region"
          },
          "toLoc": {
            "namespace": "GO",
            "name": "intracellular"
          }
        }
      },
      "source": 7,
      "target": 10,
      "key": "b2aa315fe102f4305529b9412568d806a07b61a7dbf79ac477d6dd9782ae2f746ca6da974485df575c33da179b7f3c931e209bf9ee407f7d0bda1689750fc987"
    },
    {
      "line": 159,
      "relation": "decreases",
      "evidence": "Tau13, 6C5, and HT7 efficiently depleted tau from the AD HMW fraction (97%, 82%, and 72%, respectively), whereas the other four antibodies (40E8, 4E4, p396, and Tau46) removed only a small fraction of tau (33%, 4.7%, 22%, and 21% reductions, respectively) (Figure 4A).",
      "citation": {
        "type": "PubMed",
        "reference": "28408124"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "HasQuantitativeInformation": {
          "True": true
        }
      },
      "object": {
        "location": {
          "namespace": "GO",
          "name": "cell"
        }
      },
      "source": 7,
      "target": 8,
      "key": "02c9e5bdade574399da7dee25b9b6cf491af741b8104b955faf634e48223b285b1685b498a6f8e9f35c5acc2ed4c0142c588b78044a79296226ce3c1a305cf8e"
    },
    {
      "line": 179,
      "relation": "decreases",
      "evidence": "In the tau uptake assay, 6C5 most effectively reduced tau uptake by immunodepletion (75% reduction) (Figure 4, B and C). Tau13 and HT7 showed intermediate effects (55% and 47% reductions, respectively) (Figure 4, B and C). The 40E8, p396, and 4E4 antibodies also reduced neuronal tau uptake (65%, 53%, and 47% reductions, respectively), despite their low immunodepletion efficiency (Figure 4).",
      "citation": {
        "type": "PubMed",
        "reference": "28408124"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "MeSHAnatomy": {
          "Neurons": true
        },
        "HasQuantitativeInformation": {
          "True": true
        }
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GO",
            "name": "extracellular region"
          },
          "toLoc": {
            "namespace": "GO",
            "name": "intracellular"
          }
        }
      },
      "source": 7,
      "target": 8,
      "key": "3fed2eac37adc2e4ba1c3f6dd66b655e9acaeb936769b35691ede2313d3ae7380669d3fb769584a2896ff84713f6046955f48dff11e706cfe20a4e69ba062bb3"
    },
    {
      "line": 206,
      "relation": "decreases",
      "evidence": "for example, the two phosphorylation dependent tau antibodies (40E8 and p396) were the most efficient in the human AD case with the highest level of phosphorylated tau (1266). Both 6C5 and 40E8, shown to be most effective at reducing uptake from HMW human AD brainederived tau species (Figure 3, B and C), immunostained NFTs and neuritic plaques in postmortem human AD frontal cortex sections (Figure 6); 40E8 was somewhat more reactive to neuropil threads under the conditions used.",
      "citation": {
        "type": "PubMed",
        "reference": "28408124"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 7,
      "target": 9,
      "key": "0ef5beeec898d0a5f847460daf93587894c8fcd007a53292a469cc113cfe32e9de0fb26989146093fd46682d1da103f97f2fa75bcf8ff0c5daf276391b189718"
    },
    {
      "line": 103,
      "relation": "decreases",
      "evidence": "Among the seven antibodies, Tau13 and 6C5 most efficiently removed tau (>85% reduction) from rTg4510 brain extracts on immunodepletion (Figure 2A). HT7 showed an intermediate effect (72% reduction), whereas the other four antibodies (40E8, 4E4, p396, and Tau46) removed only a small fraction of tau (5.6%, 16.6%, 8.4%, and 18% reductions, respectively) (Figure 2A).",
      "citation": {
        "type": "PubMed",
        "reference": "28408124"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "Species": {
          "10090": true
        },
        "MeSHDisease": {
          "Tauopathies": true
        },
        "HasQuantitativeInformation": {
          "True": true
        }
      },
      "object": {
        "location": {
          "namespace": "GO",
          "name": "cell"
        }
      },
      "source": 2,
      "target": 10,
      "key": "9b6d134cf9db755c9258fe5ab865c5b39e482b87b3950e6aa3009e93195e3fe8871d973bba9d1a0dc841f90a920da69a4018352294a1f26e041f106c7769b836"
    },
    {
      "line": 138,
      "relation": "decreases",
      "evidence": "The 40E8, 4E4, and p396 antibodies also reduced neuronal tau uptake by 40% to 80%, despite their low-immunodepletion efficiency (Figure 2). This finding suggests that they interacted with tau species that are prone to cellular uptake, which account for only a small fraction of all soluble tau species in the brain extract. Notably, Tau46 had little effect on tau uptake (Figure 2, B and C).",
      "citation": {
        "type": "PubMed",
        "reference": "28408124"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "Species": {
          "10090": true
        },
        "MeSHDisease": {
          "Tauopathies": true
        },
        "HasQuantitativeInformation": {
          "True": true
        }
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GO",
            "name": "extracellular region"
          },
          "toLoc": {
            "namespace": "GO",
            "name": "intracellular"
          }
        }
      },
      "source": 2,
      "target": 10,
      "key": "e45dd5f5fea23277f522b8fe7bea8a26e4fe4feebba15869e911fb0a498189b23c08b29b8850110f16aa0f87429683db1df73150ec8e78449fadc5361e6fb9db"
    },
    {
      "line": 160,
      "relation": "decreases",
      "evidence": "Tau13, 6C5, and HT7 efficiently depleted tau from the AD HMW fraction (97%, 82%, and 72%, respectively), whereas the other four antibodies (40E8, 4E4, p396, and Tau46) removed only a small fraction of tau (33%, 4.7%, 22%, and 21% reductions, respectively) (Figure 4A).",
      "citation": {
        "type": "PubMed",
        "reference": "28408124"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "HasQuantitativeInformation": {
          "True": true
        }
      },
      "object": {
        "location": {
          "namespace": "GO",
          "name": "cell"
        }
      },
      "source": 2,
      "target": 8,
      "key": "7e3f7bfc9c9905153301a355194d434bfef66090749d3f6c5ddf8ba2ae5a0c7711471707d00a95566dc2d4f69e0875feef65d67ee37b057527920408ea34071c"
    },
    {
      "line": 180,
      "relation": "decreases",
      "evidence": "In the tau uptake assay, 6C5 most effectively reduced tau uptake by immunodepletion (75% reduction) (Figure 4, B and C). Tau13 and HT7 showed intermediate effects (55% and 47% reductions, respectively) (Figure 4, B and C). The 40E8, p396, and 4E4 antibodies also reduced neuronal tau uptake (65%, 53%, and 47% reductions, respectively), despite their low immunodepletion efficiency (Figure 4).",
      "citation": {
        "type": "PubMed",
        "reference": "28408124"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        },
        "MeSHAnatomy": {
          "Neurons": true
        },
        "HasQuantitativeInformation": {
          "True": true
        }
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GO",
            "name": "extracellular region"
          },
          "toLoc": {
            "namespace": "GO",
            "name": "intracellular"
          }
        }
      },
      "source": 2,
      "target": 8,
      "key": "6e18c5ddf6e3b72f4eb5e935e84b50fdf61df4bb48fb643ef8c4c5c5791a3ae8f10391c0079d97adfb2181c2ce466a20c089aa8cc12bfac5f15eefb8ffefb05b"
    },
    {
      "line": 193,
      "relation": "association",
      "evidence": "Tau46 was the only antibody that did not show a statistically significant reduction in neuronal tau uptake (Figure 4, B and C). Tau46 bound with high apparent affinity to both recombinant and paired helical filament tau by ELISA (Table 2), demonstrating the binding of the antibody to full-length tau.",
      "citation": {
        "type": "PubMed",
        "reference": "28408124"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 8,
      "target": 6,
      "key": "b0d628fb6270b5eda0a887aaefe9d3b0ebddcfc28afa4fb7a9496a398808bbcb2d7472c979a2b187f35bdaa3e818ea24edcd562b9d1c7013d398058fd3298da3"
    },
    {
      "relation": "hasVariant",
      "source": 8,
      "target": 9,
      "key": "c4e71f1866eab20795e7e1d4b54fe09effb8b376e41712f8a130fe5192e07d83b0749cc2e2297b62cbea4bb7b1033909ea6d6423fa06166cb07543cee4249d48"
    },
    {
      "line": 192,
      "relation": "causesNoChange",
      "evidence": "Tau46 was the only antibody that did not show a statistically significant reduction in neuronal tau uptake (Figure 4, B and C). Tau46 bound with high apparent affinity to both recombinant and paired helical filament tau by ELISA (Table 2), demonstrating the binding of the antibody to full-length tau.",
      "citation": {
        "type": "PubMed",
        "reference": "28408124"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "object": {
        "modifier": "Translocation",
        "effect": {
          "fromLoc": {
            "namespace": "GO",
            "name": "extracellular region"
          },
          "toLoc": {
            "namespace": "GO",
            "name": "intracellular"
          }
        }
      },
      "source": 6,
      "target": 8,
      "key": "e66ad5a4cae29e2e4ffe93e8dd47d52c04bb0c9cd8f9825493c26bff8ff5e15b9fd60e38fa439d409b740de82d675f36b90343d3332730b55d0eceb70c773a46"
    },
    {
      "line": 193,
      "relation": "association",
      "evidence": "Tau46 was the only antibody that did not show a statistically significant reduction in neuronal tau uptake (Figure 4, B and C). Tau46 bound with high apparent affinity to both recombinant and paired helical filament tau by ELISA (Table 2), demonstrating the binding of the antibody to full-length tau.",
      "citation": {
        "type": "PubMed",
        "reference": "28408124"
      },
      "annotations": {
        "TextLocation": {
          "Results": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 6,
      "target": 8,
      "key": "5b8f17c73c74731a1256d8b0a66f87582dd2955629f893e9efa25f15daa207768211d5b2724eb95a725f9f22ca566fd7c3674970a135bfb58d969c20ab79a4b9"
    }
  ]
}